Abstract
Measurement of chromogranin-A (CgA) levels is relevant for the diagnosis of neuroendocrine neoplasms. The use of CgA testing for risk stratification of cardiovascular diseases is also increasing. The objective of our study was to determine the performances and reference values of a novel automated assay for CgA testing. The new method was compared with an enzyme-linked immunosorbent assay. Our results showed that the performances of the automated assay were satisfactory and that the agreement between the two methods was excellent. The automation of CgA testing also reduced the turnaround time of analysis and, therefore, might contribute to a faster delivery of the results to physicians.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
